Cobra venom is deadly stuff (about 20,000 fatalities a year globally), but it may also be a healer. A new drug derived from the venom has shown promise against multiple sclerosis (MS) and sister diseases affecting the nervous and immune systems. PhyloMed, a pharmaceutical company in Plantation, Fla., has synthesized a harmless peptide (small protein) from constituents of the snake’s venom, that acts as a kind of decoy. Attacks by immune system cells on myelin-the fatty material surrounding nerve fibers-disrupt signals between nerve cells to create characteristic MS lesions and paralysis. Neurotoxins from cobra venom paralyze nerve cells in much the same way. By binding to nerve cell receptors as a modified peptide instead of as a toxin, the venom-derived drug, called Immunokine, morphs into a therapeutic agent that can reverse MS’s debilitating effects. Clinical trials slated for this summer will target MS and adrenomyeloneuropathy (a progressive genetic disorder of the adrenal gland that results in nervous system deterioration).
The miracle molecule that could treat brain injuries and boost your fading memory
Discovered more than a decade ago, a remarkable compound shows promise in treating everything from Alzheimer’s to brain injuries—and it just might improve your cognitive abilities.
This scientist now believes covid started in Wuhan’s wet market. Here’s why.
How a veteran virologist found fresh evidence to back up the theory that covid jumped from animals to humans in a notorious Chinese market—rather than emerged from a lab leak.
The US crackdown on Chinese economic espionage is a mess. We have the data to show it.
The US government’s China Initiative sought to protect national security. In the most comprehensive analysis of cases to date, MIT Technology Review reveals how far it has strayed from its goals.
A horrifying new AI app swaps women into porn videos with a click
Deepfake researchers have long feared the day this would arrive.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.